Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


29.10.2018

1 Am J Surg
3 Ann Oncol
3 Ann Surg Oncol
11 BMC Cancer
5 Br J Cancer
5 Breast Cancer
4 Breast Cancer Res
11 Breast Cancer Res Treat
2 Cancer
1 Cancer Chemother Pharmacol
3 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
2 Clin Breast Cancer
1 Clin Cancer Res
1 Eur J Cancer
2 Eur J Surg Oncol
2 Gene
2 Int J Cancer
3 Int J Oncol
1 J Biol Chem
2 J Pathol
1 Lancet Oncol
11 N Engl J Med
1 NPJ Breast Cancer
3 Oncol Rep
2 Oncology (Williston Park)
3 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg

  1. VALENTE SA, Liu Y, Upadhyaya S, Tu C, et al
    The effect of wound complications following mastectomy with immediate reconstruction on breast cancer recurrence.
    Am J Surg. 2018 Oct 16. pii: S0002-9610(18)31027.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. MATHEW A, Erqou S
    Can Estrogen Receptor Status Predict for Shorter Duration of Adjuvant Trastuzumab in Early-Stage Breast Cancer?
    Ann Oncol. 2018 Oct 24. pii: 5144112. doi: 10.1093.
    PubMed     Text format    

  3. KOK M, Winer E, Loi S
    Passion for Immune checkpoint blockade in triple negative breast cancer? Comment on the IMpassion130 study.
    Ann Oncol. 2018 Oct 23. pii: 5142540. doi: 10.1093.
    PubMed     Text format    

  4. MATIKAS A, Foukakis T, Moebus V, Greil R, et al
    Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients.
    Ann Oncol. 2018 Oct 24. pii: 5144113. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  5. LANDERCASPER J
    ASO Author Reflections: Nudging Surgeon Stewards of Breast Cancer Quality Measurement Programs Toward More Patient-Centeredness.
    Ann Surg Oncol. 2018 Oct 17. pii: 10.1245/s10434-018-6923.
    PubMed     Text format    

  6. SORAN A
    ASO Author Reflections: Is Intensifying Loco-Regional Treatment in the Early Course of De Novo Stage IV Breast Cancer Reasonable?
    Ann Surg Oncol. 2018 Oct 24. pii: 10.1245/s10434-018-6924.
    PubMed     Text format    

  7. NAKHLIS F, Harrison BT, Giess CS, Lester SC, et al
    Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ.
    Ann Surg Oncol. 2018 Oct 25. pii: 10.1245/s10434-018-6937.
    PubMed     Text format     Abstract available


    BMC Cancer

  8. GEERS J, Wildiers H, Van Calster K, Laenen A, et al
    Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer.
    BMC Cancer. 2018;18:994.
    PubMed     Text format     Abstract available

  9. YANG Y, Cameron J, Bedi C, Humphris G, et al
    Fear of cancer recurrence trajectory during radiation treatment and follow-up into survivorship of patients with breast cancer.
    BMC Cancer. 2018;18:1002.
    PubMed     Text format     Abstract available

  10. ZHAO Y, Lv F, Chen S, Wang Z, et al
    Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    BMC Cancer. 2018;18:1019.
    PubMed     Text format     Abstract available

  11. DALMASSO B, Hatse S, Brouwers B, Laenen A, et al
    Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy.
    BMC Cancer. 2018;18:1014.
    PubMed     Text format     Abstract available

  12. SMITH YE, Toomey S, Napoletano S, Kirwan G, et al
    Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
    BMC Cancer. 2018;18:1016.
    PubMed     Text format     Abstract available

  13. SARINK D, Schock H, Johnson T, Chang-Claude J, et al
    Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
    BMC Cancer. 2018;18:1010.
    PubMed     Text format     Abstract available

  14. VARGA K, Hollosi A, Paszty K, Hegedus L, et al
    Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
    BMC Cancer. 2018;18:1029.
    PubMed     Text format     Abstract available

  15. JOHNSTON SJ, Ahmad D, Aleskandarany MA, Kurozumi S, et al
    Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.
    BMC Cancer. 2018;18:1027.
    PubMed     Text format     Abstract available

  16. ARCINIEGAS CALLE MC, Sandhu NP, Xia H, Cha SS, et al
    Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    BMC Cancer. 2018;18:1037.
    PubMed     Text format     Abstract available

  17. CHEN L, Qi H, Zhang L, Li H, et al
    Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:1038.
    PubMed     Text format     Abstract available

  18. REN JT, Wang MX, Su Y, Tang LY, et al
    Decelerated DNA methylation age predicts poor prognosis of breast cancer.
    BMC Cancer. 2018;18:989.
    PubMed     Text format     Abstract available


    Br J Cancer

  19. WALASZEK K, Lower EE, Ziolkowski P, Weber GF, et al
    Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0228.
    PubMed     Text format     Abstract available

  20. MUNSTER P, Krop IE, LoRusso P, Ma C, et al
    Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
    Br J Cancer. 2018 Oct 26. pii: 10.1038/s41416-018-0235.
    PubMed     Text format     Abstract available

  21. TAMBOUR M, Holt M, Speyer A, Christensen R, et al
    Manual lymphatic drainage adds no further volume reduction to Complete Decongestive Therapy on breast cancer-related lymphoedema: a multicentre, randomised, single-blind trial.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0306.
    PubMed     Text format     Abstract available

  22. BERTUCCI F, Finetti P, Simeone I, Hendrickx W, et al
    The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0309.
    PubMed     Text format     Abstract available

  23. LANGBALLE R, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
    Statin use and risk of contralateral breast cancer: a nationwide cohort study.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0252.
    PubMed     Text format     Abstract available


    Breast Cancer

  24. RANGEL J, Tomas MT, Fernandes B
    Physical activity and physiotherapy: perception of women breast cancer survivors.
    Breast Cancer. 2018 Oct 25. pii: 10.1007/s12282-018-0928.
    PubMed     Text format     Abstract available

  25. YAGI T, Fujiishi K, Hasegawa A, Otsuka T, et al
    Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients.
    Breast Cancer. 2018 Oct 22. pii: 10.1007/s12282-018-0918.
    PubMed     Text format     Abstract available

  26. DEN OUDEN MEM, Pelgrum-Keurhorst MN, Uitdehaag MJ, De Vocht HM, et al
    Intimacy and sexuality in women with breast cancer: professional guidance needed.
    Breast Cancer. 2018 Oct 25. pii: 10.1007/s12282-018-0927.
    PubMed     Text format     Abstract available

  27. LIU M, Zhou S, Wang J, Zhang Q, et al
    Identification of genes associated with survival of breast cancer patients.
    Breast Cancer. 2018 Oct 19. pii: 10.1007/s12282-018-0926.
    PubMed     Text format     Abstract available

  28. PALUMBO I, Mariucci C, Falcinelli L, Perrucci E, et al
    Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity.
    Breast Cancer. 2018 Oct 19. pii: 10.1007/s12282-018-0923.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  29. MCKNIGHT BN, Viola-Villegas NT
    Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging.
    Breast Cancer Res. 2018;20:130.
    PubMed     Text format     Abstract available

  30. LIU X, Cao M, Palomares M, Wu X, et al
    Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts.
    Breast Cancer Res. 2018;20:127.
    PubMed     Text format     Abstract available

  31. HORTOBAGYI GN
    Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
    Breast Cancer Res. 2018;20:123.
    PubMed     Text format     Abstract available

  32. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
    Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res. 2018;20:124.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  33. HE X, Ji J, Dong R, Liu H, et al
    Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    Breast Cancer Res Treat. 2018 Oct 19. pii: 10.1007/s10549-018-5005.
    PubMed     Text format     Abstract available

  34. ALTUNDAG K
    Extranodular extension in sentinel lymph node-positive breast cancer might predict further initiation of completion axillary lymph node dissection.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-5019.
    PubMed     Text format    

  35. WU T, Sultan LR, Tian J, Cary TW, et al
    Machine learning for diagnostic ultrasound of triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4984.
    PubMed     Text format     Abstract available

  36. BLANCO C, Markowitz JC, Hellerstein DJ, Nezu AM, et al
    A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4994.
    PubMed     Text format     Abstract available

  37. RYU JM, Choi HJ, Kim I, Nam SJ, et al
    Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5015.
    PubMed     Text format     Abstract available

  38. JEREVALL PL, Brock J, Palazzo J, Wieczorek T, et al
    Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
    Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5013.
    PubMed     Text format     Abstract available

  39. VAN DEN BERG MMGA, Kok DE, Posthuma L, Kamps L, et al
    Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy.
    Breast Cancer Res Treat. 2018 Oct 23. pii: 10.1007/s10549-018-5014.
    PubMed     Text format     Abstract available

  40. CABEL L, Carton M, Cheaib B, Pierga JY, et al
    Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
    Breast Cancer Res Treat. 2018 Oct 24. pii: 10.1007/s10549-018-5017.
    PubMed     Text format     Abstract available

  41. JONCZYK MM, Jean J, Graham R, Chatterjee A, et al
    Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5018.
    PubMed     Text format     Abstract available

  42. OHARA AM, Naoi Y, Shimazu K, Kagara N, et al
    PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5020.
    PubMed     Text format     Abstract available

  43. LIU GY, Li JW, Zuo WJ, Ivanova D, et al
    Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5024.
    PubMed     Text format     Abstract available


    Cancer

  44. LAMBERTINI M, Martel S, Campbell C, Guillaume S, et al
    Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
    Cancer. 2018 Oct 18. doi: 10.1002/cncr.31784.
    PubMed     Text format     Abstract available

  45. CAUDLE AS, Kuerer HM, Krishnamurthy S, Shin K, et al
    Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study.
    Cancer. 2018 Oct 25. doi: 10.1002/cncr.31825.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  46. BAI Y, Wu HW, Zhang YH
    Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis.
    Cancer Chemother Pharmacol. 2018 Oct 24. pii: 10.1007/s00280-018-3703.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  47. NIEHOFF NM, Nichols HB, Zhao S, White AJ, et al
    Adult physical activity and breast cancer risk in women with a family history of breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2018 Oct 17. pii: 1055-9965.EPI-18-0674.
    PubMed     Text format     Abstract available

  48. MARIOTTO AB, Zou Z, Zhang F, Howlader N, et al
    Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2018 Oct 18. pii: 1055-9965.EPI-17-1129.
    PubMed     Text format     Abstract available

  49. TAO L, Schwab RB, San Miguel Y, Gomez SL, et al
    Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California.
    Cancer Epidemiol Biomarkers Prev. 2018 Oct 17. pii: 1055-9965.EPI-18-0353.
    PubMed     Text format     Abstract available


    Cancer Lett

  50. XIAO YS, Zeng, Liang YK, Wu Y, et al
    Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.
    Cancer Lett. 2018 Oct 15. pii: S0304-3835(18)30608.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  51. NAKAGAWA M, Ikeuchi M, Morimoto M, Takechi H, et al
    Phase II Study of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy for Operable Breast Cancer Patients (N-1 Study).
    Clin Breast Cancer. 2018 Sep 27. pii: S1526-8209(18)30262.
    PubMed     Text format     Abstract available

  52. PAN H, Zhang K, Wang M, Ling L, et al
    Palliative Local Surgery for Locally Advanced Breast Cancer Depending on Hormone Receptor Status in Elderly Patients.
    Clin Breast Cancer. 2018 Sep 27. pii: S1526-8209(18)30510.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  53. GRELLETY T, Callens C, Richard E, Briaux A, et al
    Enhancing abiraterone acetate efficacy in androgen receptor-positive triple negative breast cancer: Chk1 as a potential target.
    Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-18-1469.
    PubMed     Text format     Abstract available


    Eur J Cancer

  54. HURVITZ SA, Quek RGW, Turner NC, Telli ML, et al
    Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
    Eur J Cancer. 2018;104:160-168.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  55. SPRONK PER, Volders JH, van den Tol P, Smorenburg CH, et al
    Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit.
    Eur J Surg Oncol. 2018 Oct 17. pii: S0748-7983(18)31447.
    PubMed     Text format     Abstract available

  56. LAI HW, Wang CC, Lai YC, Chen CJ, et al
    The learning curve of robotic nipple sparing mastectomy for breast cancer: An analysis of consecutive 39 procedures with cumulative sum plot.
    Eur J Surg Oncol. 2018 Oct 17. pii: S0748-7983(18)31440.
    PubMed     Text format     Abstract available


    Gene

  57. MA R, Zhai X, Zhu X, Zhang L, et al
    LINC01585 functions as a regulator of gene expression by the CAMP/CREB signaling pathway in breast cancer.
    Gene. 2018 Oct 23. pii: S0378-1119(18)31102-8. doi: 10.1016/j.gene.2018.
    PubMed     Text format     Abstract available

  58. JAHANGIRI R, Jamialahmadi K, Gharib M, Razavi AE, et al
    Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients.
    Gene. 2018 Oct 22. pii: S0378-1119(18)31099-0. doi: 10.1016/j.gene.2018.
    PubMed     Text format     Abstract available


    Int J Cancer

  59. HOUGHTON SC, Eliassen AH, Zhang SM, Selhub J, et al
    Plasma B-vitamin and one-carbon metabolites and risk of breast cancer before and after folic acid fortification in the US.
    Int J Cancer. 2018 Oct 22. doi: 10.1002/ijc.31934.
    PubMed     Text format     Abstract available

  60. BENS A, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
    Non-aspirin NSAIDs and contralateral breast cancer risk.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31949.
    PubMed     Text format    


    Int J Oncol

  61. KIM SK, Kim K, Ryu JW, Ryu TY, et al
    The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.
    Int J Oncol. 2018 Oct 26. doi: 10.3892/ijo.2018.4608.
    PubMed     Text format     Abstract available

  62. TAN Y, Wang Q, Xie Y, Qiao X, et al
    Identification of FOXM1 as a specific marker for triplenegative breast cancer.
    Int J Oncol. 2018 Oct 19. doi: 10.3892/ijo.2018.4598.
    PubMed     Text format     Abstract available

  63. FURLAN A, Vercamer C, Heliot L, Wernert N, et al
    Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells.
    Int J Oncol. 2018 Oct 24. doi: 10.3892/ijo.2018.4605.
    PubMed     Text format     Abstract available


    J Biol Chem

  64. GODBOLE M, Togar T, Patel K, Dharavath B, et al
    Up-regulation of the kinase gene SGK1 by progesterone activates the AP-1-NDRG1 axis in both PR-positive and -negative breast cancer cells.
    J Biol Chem. 2018 Oct 18. pii: RA118.002894. doi: 10.1074/jbc.RA118.002894.
    PubMed     Text format     Abstract available


    J Pathol

  65. LIU RZ, Vo TM, Jain S, Choi WS, et al
    NFIB promotes cell survival by directly suppressing p21 transcription in p53-mutated triple-negative breast cancer.
    J Pathol. 2018 Oct 22. doi: 10.1002/path.5182.
    PubMed     Text format     Abstract available

  66. MCCART REED AE, Kalaw E, Nones K, Bettington M, et al
    Phenotypic and molecular dissection of Metaplastic Breast Cancer and the prognostic implications.
    J Pathol. 2018 Oct 22. doi: 10.1002/path.5184.
    PubMed     Text format     Abstract available


    Lancet Oncol

  67. VELIKOVA G, Williams LJ, Willis S, Dixon JM, et al
    Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
    Lancet Oncol. 2018 Oct 15. pii: S1470-2045(18)30515.
    PubMed     Text format     Abstract available


    N Engl J Med

  68. NEWMAN LA
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1681-2.
    PubMed     Text format    


  69. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations; Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2018;379:1585.
    PubMed     Text format    

  70. TURNER NC, Slamon DJ, Ro J, Bondarenko I, et al
    Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
    N Engl J Med. 2018 Oct 20. doi: 10.1056/NEJMoa1810527.
    PubMed     Text format     Abstract available

  71. SCHMID P, Adams S, Rugo HS, Schneeweiss A, et al
    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2018 Oct 20. doi: 10.1056/NEJMoa1809615.
    PubMed     Text format     Abstract available

  72. MCCAW ZR, Wei LJ, Kim DH
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1681.
    PubMed     Text format    


  73. Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1680-1682.
    PubMed     Text format    

  74. CHLEBOWSKI RT, Pan K
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1684.
    PubMed     Text format    

  75. PATEL A, Gupta VG
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683-4.
    PubMed     Text format    

  76. LOVE RR
    Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683.
    PubMed     Text format    


  77. Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018;379:1683-1685.
    PubMed     Text format    

  78. CHENG Y, Wu Y, Wu L
    Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2018;379:1680-1.
    PubMed     Text format    


    NPJ Breast Cancer

  79. KEENE KS, King T, Hwang ES, Peng B, et al
    Molecular determinants of post-mastectomy breast cancer recurrence.
    NPJ Breast Cancer. 2018;4:34.
    PubMed     Text format     Abstract available


    Oncol Rep

  80. WANG L, Shi H, Zhang X, Zhang X, et al
    I157172, a novel inhibitor of cystathionine gamma-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3.
    Oncol Rep. 2018 Oct 16. doi: 10.3892/or.2018.6798.
    PubMed     Text format     Abstract available

  81. LI W, Yang H, Li X, Han L, et al
    Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer.
    Oncol Rep. 2018 Oct 18. doi: 10.3892/or.2018.6805.
    PubMed     Text format     Abstract available

  82. EL-TABBA' RM, Mathew P, Masocha W, Khajah MA, et al
    COL3 enhances the antiproliferative and proapoptotic effects of paclitaxel in breast cancer cells.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6815.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  83. WEISS J, Afghahi A, Shagisultanova E, Diamond JR, et al
    Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
    Oncology (Williston Park). 2018;32:513-5.
    PubMed     Text format    

  84. SPARANO JA
    Gene Expression Assays in Early-Stage Breast Cancer.
    Oncology (Williston Park). 2018;32:510-2.
    PubMed     Text format    


    PLoS One

  85. ALOTAIBI RM, Rezk HR, Juliana CI, Guure C, et al
    Breast cancer mortality in Saudi Arabia: Modelling observed and unobserved factors.
    PLoS One. 2018;13:e0206148.
    PubMed     Text format     Abstract available

  86. DUMANE VA, Bakst R, Green S
    Dose to organs in the supraclavicular region when covering the Internal Mammary Nodes (IMNs) in breast cancer patients: A comparison of Volumetric Modulated Arc Therapy (VMAT) versus 3D and VMAT.
    PLoS One. 2018;13:e0205770.
    PubMed     Text format     Abstract available

  87. COVARRUBIAS G, Cha A, Rahmy A, Lorkowski M, et al
    Imaging breast cancer using a dual-ligand nanochain particle.
    PLoS One. 2018;13:e0204296.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  88. GURYEV EL, Volodina NO, Shilyagina NY, Gudkov SV, et al
    Radioactive ((90)Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer.
    Proc Natl Acad Sci U S A. 2018;115:9690-9695.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: